Use of levosimendan in acute and advanced heart failure: short review on available real-world data

References

• Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure. Circulation. 2013;128(16). doi:10.1161/CIR.0b013e31829e8776
   Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891–975. doi:10.1002/ejhf.59227207191
   PubMed Web of Science ®Google Scholar
• Fedele F, Kivikko M, Tschöpe C, et al. Repetitive levosimendan treatment in the management of advanced heart failure. Eur Hear J Suppl. 2018. doi:10.1093/eurheartj/suy040
   PubMed Web of Science ®Google Scholar
• McMurray JJV. Systolic heart failure. N Engl J Med. 2010;362(3):228–238. doi:10.1056/NEJMcp090939220089973
   PubMed Web of Science ®Google Scholar
• Chen J, Normand S-LT, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for medicare beneficiaries, 1998-2008. Jama. 2011;306(15):1669–1678. doi:10.1001/jama.2011.147422009099
   PubMed Web of Science ®Google Scholar
• Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12517230. Accessed February 21, 2019.12517230
   PubMed Web of Science ®Google Scholar
• Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9(6–7):684–694. doi:10.1016/j.ejheart.2007.04.00317481947
   PubMed Web of Science ®Google Scholar
• Nizamic T, Murad MH, Allen LA, et al. Ambulatory inotrope infusions in advanced heart failure. JACC Hear Fail. 2018;6(9):757–767. doi:10.1016/j.jchf.2018.03.019
   PubMed Web of Science ®Google Scholar
• Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482–1487. doi:10.1161/CIRCULATIONAHA.107.69690617724259
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260–266. doi:10.1016/j.ahj.2007.01.04117643574
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Altenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol. 2014;174(2):360–367. doi:10.1016/j.ijcard.2014.04.11124780540
   PubMed Web of Science ®Google Scholar
• Husedzinovic I, Husedzinovic S, Milanovic R. Levosimendan in acute heart failure. Signa Vitae - A J Intensive Care Emerg Med. 2017. doi:10.22514/sv31.022008.3
   Google Scholar
• García-González MJ, Jorge-Pérez P, Jiménez-Sosa A, Acea AB, Lacalzada Almeida JB, Ferrer Hita JJ. Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study. Cardiovasc Ther. 2015;33(4):193–199. doi:10.1111/1755-5922.1213225959786
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Akkila J, Hasenfuss G, et al. Heart failure hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll cardiol. 36;2000. doi:10.1016/S0735-1097(00)00961-X
   PubMed Web of Science ®Google Scholar
• De Hert SG, Wikström BG, Meyer S, et al. Levosimendan: molecular mechanisms and clinical implications. Int J Cardiol. 2011. doi:10.1016/j.ijcard.2011.07.022
   PubMed Web of Science ®Google Scholar
• Jia Z, Guo M, Zhang Y-Q, Liang H-Q, Zhang L-Y, Song Y. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology. 2014;128(2):195–201. doi:10.1159/00035786424751462
   PubMed Web of Science ®Google Scholar
• Pollesello P, Parissis J, Kivikko M, Harjola V-P. Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol. 2016;209:77–83. doi:10.1016/j.ijcard.2016.02.01426882190
   PubMed Web of Science ®Google Scholar
• Belletti A, Castro ML, Silvetti S, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth. 2015;115(5):656–675. doi:10.1093/bja/aev28426475799
   PubMed Web of Science ®Google Scholar
• Sorsa T, Pollesello P, Rosevear PR, Drakenberg T, Kilpeläinen I. Stereoselective binding of levosimendan to cardiac troponin C causes Ca 2+-sensitization. Eur J Pharmacol. 2004. doi:10.1016/j.ejphar.2003.12.006
   PubMed Web of Science ®Google Scholar
• Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276(12):9337–9343. doi:10.1074/jbc.M00748420011113122
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Andreini D, Farina S, et al. Levosimendan improves exercise performance in patients with advanced chronic heart failure. ESC Hear Fail. 2015. doi:10.1002/ehf2.12047
   PubMedGoogle Scholar
• Nieminen MS, Fonseca C, Brito D, Wikström G. The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure. Eur Hear Journal, Suppl. 2017. doi:10.1093/eurheartj/sux003
   PubMed Web of Science ®Google Scholar
• Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology. 1994;81(4):974–987. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7943849. Accessed May 26, 2019.7943849
   PubMed Web of Science ®Google Scholar
• Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol. 1998;31(5):741–749. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9593074. Accessed February 20, 2019.9593074
   PubMed Web of Science ®Google Scholar
• Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006;148(5):696–702. doi:10.1038/sj.bjp.070678116715115
   PubMed Web of Science ®Google Scholar
• Höhn J, Pataricza J, Petri A, et al. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol. 2004;94(6):271–273. doi:10.1111/j.1742-7843.2004.pto940603.x15228498
   PubMed Web of Science ®Google Scholar
• Hansen MS, Andersen A, Nielsen-Kudsk JE. Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ. 2018. doi:10.1177/2045894018790905
   Web of Science ®Google Scholar
• Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90(1):5–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10624967. Accessed February 20, 2019.10624967
   PubMed Web of Science ®Google Scholar
• Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):26G–31G. doi:10.1016/j.amjcard.2005.07.018
   PubMed Web of Science ®Google Scholar
• Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol. 2007;150(7):851–861. doi:10.1038/sj.bjp.070715717325658
   PubMed Web of Science ®Google Scholar
• Grossini E, Caimmi PP, Platini F, et al. Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs. Cardiovasc Drugs Ther. 2010;24(1):5–15. doi:10.1007/s10557-010-6217-020162343
   PubMed Web of Science ®Google Scholar
• Caimmi PP, Molinari C, Uberti F, et al. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg. 2011;39(4):e59–e67. doi:10.1016/j.ejcts.2010.11.04421247774
   PubMed Web of Science ®Google Scholar
• Onichimowski D, Nosek K, Goraj R, et al. Use of levosimendan in the treatment of cerebral vascular vasospasm: a case study. Drug Des Devel Ther. 2018. doi:10.2147/DDDT.S158237
   PubMed Web of Science ®Google Scholar
• Sandell EP, Hayha M, Antila S, et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol. 1995; 26(Suppl 1):S57–S62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8907132. Accessed February 20, 2019. doi:10.1097/00005344-199506261-000088907132
   PubMed Web of Science ®Google Scholar
• Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24 hr continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002;40(10):465–471. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12395979. Accessed February 20, 2019.12395979
   PubMed Web of Science ®Google Scholar
• Puttonen J, Kantele S, Ruck A, et al. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment. J Clin Pharmacol. 2008;48(4):445–454. doi:10.1177/009127000731339018303124
   PubMed Web of Science ®Google Scholar
• Ishihara S, Gayat E, Sato N, et al. Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure. Clin Res Cardiol. 2016;105(12):971–980. doi:10.1007/s00392-016-1009-627314418
   PubMed Web of Science ®Google Scholar
• Bouchez S, Fedele F, Giannakoulas G, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018. doi:10.1007/s10557-018-6838-2
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Hear Fail. 2013;1(2):103–111. doi:10.1016/j.jchf.2012.12.004
   PubMed Web of Science ®Google Scholar
• de Lissovoy G, Fraeman K, Teerlink JR, et al. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Heal Econ. 2010;11(2):185–193. doi:10.1007/s10198-009-0165-2
   PubMed Web of Science ®Google Scholar
• Moiseyev VS, Põder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23(18):1422–1432. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12208222. Accessed February 22, 2019. doi:10.1053/euhj.2001.315812208222
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure. JAMA. 2007;297(17):1883. doi:10.1001/jama.297.17.188317473298
   PubMed Web of Science ®Google Scholar
• Allou N, Allyn J, Bouchet B, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care. 2019. doi:10.1186/s13613-019-0503-1
   PubMed Web of Science ®Google Scholar
• Farmakis D, Alvarez J, Ben GT, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303–312. doi:10.1016/j.ijcard.2016.07.20227498374
   PubMed Web of Science ®Google Scholar
• Sangalli F, Avalli L, Laratta M, et al. Effects of levosimendan on endothelial function and hemodynamics during weaning from veno-arterial extracorporeal life support. J Cardiothorac Vasc Anesth. 2016;30(6):1449–1453. doi:10.1053/j.jvca.2016.03.13927495966
   PubMed Web of Science ®Google Scholar
• Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018. doi:10.1002/ejhf.1236
   Web of Science ®Google Scholar
• Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16(8):898–906. doi:10.1002/ejhf.11824920349
   PubMed Web of Science ®Google Scholar
• Comín-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018. doi:10.1002/ejhf.1145
   Web of Science ®Google Scholar
• García-González MJ, de Mora-Martín M, López-Fernández S, et al. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther. 2013;27(6):573–579. doi:10.1007/s10557-013-6476-723887741
   PubMed Web of Science ®Google Scholar
• Giannakoulas G, Harjola V-P, Oliva F, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018. doi:10.1007/s10557-018-6838-2
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (London, England). 2002;360(9328):196–202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12133653. Accessed February 22, 2019.
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21(6):431–435. doi:10.1007/s10557-007-6066-717952581
   PubMed Web of Science ®Google Scholar
• Lannemyr L, Ricksten SE, Rundqvist B, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double-blind controlled trial. J Am Heart Assoc. 2018;7:16. doi:10.1161/JAHA.117.008455
   Web of Science ®Google Scholar
• Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail. 2007;13(6):417–421. doi:10.1016/j.cardfail.2007.03.00517675054
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery J-L, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015;37(1):67–119. doi:10.1093/eurheartj/ehv31726320113
   PubMed Web of Science ®Google Scholar
• Jiang R, Zhao Q-H, Wu W-H, et al. Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension. Clin Respir J. 2018;12(4):1518–1525. doi:10.1111/crj.1269928862394
   PubMed Web of Science ®Google Scholar
• Martyniuk TV, Arkhipova OA, Kobal’ EA, Danilov NM, Chazova IE. Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension. Ter Arkh. 2012;84(9):83–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23091860. Accessed February 22, 2019.23091860
   PubMed Web of Science ®Google Scholar
• Poelzl G, Zwick RH, Grander W, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008;33(5):368–373. doi:10.1007/s00059-008-3051-218773157
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Yontar C, Erdem A, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels. 2009;24(1):16–21. doi:10.1007/s00380-008-1077-219165563
   PubMed Web of Science ®Google Scholar
• Mishra A, Kumar B, Dutta V, Arya VK, Mishra AK. Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. J Cardiothorac Vasc Anesth. 2016;30(3):639–646. doi:10.1053/j.jvca.2016.01.01527321790
   PubMed Web of Science ®Google Scholar